Nguyen Que Thanh Thanh, Kim Jihye, Yoo Hee Chan, Lee Eun-Ju
Department of Obstetrics and Gynecology, School of Medicine, Chung-Ang University, Seoul 06974, Republic of Korea; Organoid Medical Research Center, Chung-Ang University, Seoul 06974, Republic of Korea.
Department of Obstetrics and Gynecology, School of Medicine, Chung-Ang University, Seoul 06974, Republic of Korea.
Crit Rev Oncol Hematol. 2025 Jun;210:104706. doi: 10.1016/j.critrevonc.2025.104706. Epub 2025 Mar 22.
Epithelial ovarian cancer (EOC) is the most fetal gynecological malignancy. The main causes of treatment failure are primary and acquired chemoresistance that remains a major therapeutic challenge. The mechanisms underlying chemoresistance in EOC are complex and not fully understood. This review explores novel therapeutic strategies targeting chemoresistant EOC, including advanced drug delivery systems, targeting non-coding RNAs, peptide-based therapies, immunotherapy, and the use of poly-ADP ribose polymerase inhibitors. By summarizing the latest research and potential treatments, this review aims to contribute to the development of more effective therapies for patients with chemoresistant EOC.
上皮性卵巢癌（EOC）是最致命的妇科恶性肿瘤。治疗失败的主要原因是原发性和获得性化疗耐药，这仍然是一个重大的治疗挑战。EOC中化疗耐药的潜在机制复杂且尚未完全了解。本综述探讨了针对化疗耐药EOC的新型治疗策略，包括先进的药物递送系统、靶向非编码RNA、基于肽的疗法、免疫疗法以及聚ADP核糖聚合酶抑制剂的使用。通过总结最新研究和潜在治疗方法，本综述旨在为开发更有效的化疗耐药EOC患者治疗方法做出贡献。
